Home » Stocks » BLPH

Bellerophon Therapeutics, Inc. (BLPH)

Stock Price: $6.50 USD -0.63 (-8.84%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $6.57 +0.07 (1.08%) Nov 25, 7:58 PM

Stock Price Chart

Key Info

Market Cap 61.74M
Revenue (ttm) n/a
Net Income (ttm) -20.80M
Shares Out 9.50M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $6.50
Previous Close $7.13
Change ($) -0.63
Change (%) -8.84%
Day's Open 7.14
Day's Range 6.35 - 7.14
Day's Volume 173,193
52-Week Range 3.19 - 26.00

More Stats

Market Cap 61.74M
Enterprise Value 9.49M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 9.50M
Float 8.62M
EPS (basic) -3.28
EPS (diluted) -3.17
FCF / Share -1.73
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 162,752
Short Ratio 4.01
Short % of Float 1.89%
Beta -0.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.82
Revenue n/a
Operating Income -22.45M
Net Income -20.80M
Free Cash Flow -16.37M
Net Cash 52.25M
Net Cash / Share 5.50
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -33.50%
ROE -78.17%
ROIC 974.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(307.69% upside)
Current: $6.50
Target: 26.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-17.47-27.88-24.60-23.76-46.57-59.75-62.00-46.23
Net Income-13.272.81-54.82-23.81-46.46-59.67-62.00-46.23
Shares Outstanding4.503.832.601.000.820.53--
Earnings Per Share-2.95-5.07-21.11-23.70-56.85-113.39--
Operating Cash Flow-12.94-15.50-15.90-17.21-46.26-70.56-57.23-36.22
Capital Expenditures----0.02-0.46--0.73-3.48
Free Cash Flow-12.94-15.50-15.90-17.24-46.72-70.56-57.96-39.70
Cash & Equivalents9.9816.7532.2220.1724.0726.08--
Total Debt2.32-------
Net Cash / Debt7.6616.7532.2220.1724.0726.08--
Book Value3.593.86-2.5917.9930.3422.94-15.74-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bellerophon Therapeutics, Inc.
Country United States
Employees 18
CEO Fabian Tenenbaum

Stock Information

Ticker Symbol BLPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BLPH
IPO Date February 13, 2015


Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.